RiteMED Clindamycin Use In Pregnancy & Lactation

Pregnancy: (Pregnancy Category B): Clindamycin crosses the placenta in humans. After multiple doses, amniotic fluid concentrations were about 30% of maternal concentrations. Clindamycin was widely distributed in fetal tissues with the highest concentration found in liver. Since there are no adequate and well controlled studies in pregnant women, clindamycin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
The US Centers for Disease Control and Prevention recommends that screening and/or treatment for bacterial vaginosis (BV) in pregnant women as clinically indicated should be conducted at the first prenatal visit. For the treatment of BV and reduction in the incidence of adverse pregnancy outcomes associated with BV (e.g., preterm birth), particularly in pregnant women at high risk for complications of pregnancy, oral clindamycin is recommended [see Dosage & Administration].
Lactation: Clindamycin is distributed into human milk, achieving breast milk concentrations of 0.7 to 3.8 mcg/mL at dosages of 150 mg orally to 600 mg intravenously. Since Clindamycin may cause serious adverse effects to the infant, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the drug to the mother.